Tagraxofusp
- Generic Name
- Tagraxofusp
- Brand Names
- Elzonris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2055491-00-2
- Unique Ingredient Identifier
- 8ZHS5657EH
- Background
Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli. Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for ...
- Indication
Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). In the US, it is approved for use in adults and pediatric patients over 2 years old. In Europe, it is only approved for use in adults.
- Associated Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Associated Therapies
- First-line Therapy
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02270463
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02113982
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Presbyterian Shady Side, Pittsburgh, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸H. Lee Moffiitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.